

Supplementary Table S1. Characteristics of the population based on JIA subtype.

	Entire cohort (136)	pOligo (55)	eOligo (21)	Poli (60)	Test and <i>p</i> -value
Female, n %	102 (75%)	36 (65.5%)	17 (81%)	49 (81.7%)	NS
Age at diagnosis, m (R)	3 (1-15)	2 (1-13)	3 (1-15)	4 (1-14)	0.049
Uveitis history n %	50 (40.4%)	32 (58.2%)	8 (38.1%)	15 (25%)	χ^2 13.1 <i>p</i> < 0.001
ANA positivity	99 (72.8%)	45 (81.8%)	13 (61.9%)	41 (68.3%)	NS
JADAS10 onset, m (R)	17.3 (2-41.7)	14.1 (3.7-21.6)	13.2 (2-24.7)	21.9 (10-41.7)	<0.001
CHAQ onset, m (R)	0.87 (0-2.4)	0.6 (0-1.9)	10.7 (0-1.9)	1.4 (0-2.4)	<0.001
ESR onset mm/h, m (R)	45 (2-120)	45.5 (2-96)	37 (6-120)	49 (2-2120)	NS
CRP onset mg/dl, m (R)	1.29 (0-17)	1.32 (0-17)	0.7 (0.2-8.4)	1.34 (0-10.2)	NS
Type of biologics	ADA 79 ETA 57	ADA 42 ETA 13	ADA 38 ETA 13	ADA29 ETA31	χ^2 13.38 <i>p</i> < 0.001
Characteristics of population when the biologic was started					
Age m (R)	6 (1-16)	6 (1-13)	7 (2-15)	6 (1-14)	NS
n. of active joints	4 (0-18)	2 (0-6)	4 (0-8)	7 (0-18)	p <i>p</i> < 0.001
Active uveitis	36 (26.5%)	24	6	6	χ^2 17.28 <i>p</i> < 0.001
ESR	21.5 (0-120)	11 (0-66)	35 (6-68)	24 (0-120)	0.018
CRP	0.41 (0.02-32)	0.32 (0.02-32)	1.5 (0.08-12.1)	0.36 (0.09-12.5)	NS
JADAS10	17.2 (0-34.4)	12.5 (0-23)	17.5 (0-27.8)	19.7 (0-34.4)	<i>p</i> < 0.001
CHAQ	1 (0-2.5)	0.5 (0-2.2)	0.8 (0-2.4)	1.6 (0-2.5)	<i>p</i> < 0.001
Concomitant therapy	111 MTX (81.6%)	45	15	50	NS
Systemic corticosteroids	28 (20.6%)	9	5	14	NS
Time between diagnosis and B (months)	12 (0-127)	24 (1-127)	21 (5-60)	7.5 (0-93)	<i>p</i> < 0.001
Time to achieve inactivity therapy months	4 (1-32)	3 (1-30)	3 (1-32)	4 (1-24)	NS
Last item that achieves remission					
Arthritis	108	35	18	55	χ^2 14.93 <i>p</i> < 0.005
Uveitis	23	17	2	4	
Both	5	3	1	1	
Duration of remission on Tp months	23 (3-64)	22 (3-64)	28 (14-58)	22 (3.5-60)	NS
Duration of therapy	30 (6-90)	30 (7-90)	32 (15-60)	30 (6-65)	NS
Time free from relapse out of therapy months	6 (0.5-96)	6 (0.5-60)	4 (0.5-96)	6 (0.5-68)	NS
n. of pts who relapsed	106 (79.4%)	43 (78.2%)	18 (85.7%)	47 (78.3%)	NS
Type of flare					
Arthritis	71 (66.9%)	21	13	37	χ^2 9.72 <i>p</i> < 0.04
Uveitis	19 (17.9%)	11	2	6	
Both	18 (16.9%)	11	3	4	
Modality to stop B					
Lengthening intervals	104 (76.5%)	42	16	46	NS
Reduction of dose	25 (18.4)	6	5	14	
Abrupt	16 (11.8%)	10	1	5	
Duration of decalage of B	6 (0-22)	6 (0-22)	6 (0-20)	6 (0-22)	NS
Modality to stop concomitant					
Lengthening intervals	21 (15.4%)	11	2	8	NS
Reduction of dose	32 (23.5%)	11	5	16	
Abrupt	36 (26.5%)	15	6	15	

m: median, N: number, R: range, pOligo: persistent oligoarthritis, eOligo: extended oligoarthritis, Poli: polyarticular, JIA: juvenile idiopathic arthritis, JADAS10: Juvenile Arthritis Disease Activity Score 10, CHAQ: Childhood Health Assessment Questionnaire, ESR: erythrocyte sedimentation rate, CRP: C-reactive protein, B: biologics, Tp: therapy.

Supplementary Table S2. Characteristics of the population, according to the history of uveitis.

	Entire cohort (136)	History of uveitis (55)	No uveitis history (81)	Test and p-value
Female, n %	102 (75%)	42/55	60/81	NS
Age at diagnosis, m (R)	3 (1-15)	2 (1-13)	4 (1-15)	p<0.001
Type of JIA				
pOligo, n (%)	55 (40.4%)	32	23	χ^2 13.1 p<0.001
eOligo, n (%)	21 (15.4%)	8	13	
Poli, n (%)	60 (44.1%)	15	45	
ANA positivity	99 (72.8%)	46 (83.6%)	53 (65.4%)	χ^2 5.4 p<0.0001
JADAS10 onset, m (R)	17.3 (2-41.7)	15.35 (2-33.7)	18.9 (3-41.7)	NS
CHAQ onset, m (R)	0.87 (0-2.4)	0.75 (0-2.3)	1.1 (0-2.4)	NS
ESR onset mm/h, m (R)	45 (2-120)	48 (2-120)	40 (2-120)	NS
CRP onset mg/dl, m (R)	1.29 (0-17)	1.7 (0-17)	1.1 (0-7.9)	NS
Type of biologics	ADA 79 ETA 57	ADA 48 ETA 7	ADA 31 ETA 50	χ^2 32.3 p<0.0001
Characteristics of population when the biologic was started				
Age m (R)	6 (1-16)	6 (1-13)	6 (1-16)	NS
n. of active joints	4 (0-18)	2 (0-15)	5 (1-18)	p<0.001
Active uveitis	36 (26.5%)	36	0	χ^2 73.6 p<0.0001
ESR	21.5 (0-120)	25 (0-86)	10 (0-120)	NS
CRP	0.41 (0.02-32)	0.46 (0.05-11)	0.36 (0.02-32)	NS
JADAS10	17.2 (0-34.4)	15.2 (0-27.2)	17.8 (2-34.4)	p<0.02
CHAQ	1 (0-2.5)	0.7 (0-2.2)	1.2 (0-2.5)	p<0.007
Concomitant therapy	111 MTX (81.6%)	43/55	68/81	NS
Systemic corticosteroids	28 (20.6%)	10/55	18/81	NS
Time between diagnosis and B (months)	12 (0-127)	29 (2-127)	10 (0-117)	p<0.0001
Time to achieve inactivity therapy months	4 (1-32)	3 (1-32)	4 (1-24)	P 0.045
Last item that achieves remission				
Arthritis	108	27	81	χ^2 51.9 p<0.0001
Uveitis	23	23	0	
Both	5	5	0	
Duration of remission on Tp months	23 (3-64)	23 (6-64)	23 (3-58)	NS
Duration of therapy	30 (6-90)	29 (7-90)	30 (6-72)	NS
Time free from relapse out of therapy months	6 (0.5-96)	4 (0.5-60)	7 (0.5-96)	p<0.001
n. of pts who relapsed	106 (79.4%)	50 (90.9%)	58 (71.6%)	χ^2 7.46 p0.006
Type of flare				
Arthritis	71 (66.9%)	15	56	χ^2 53.2 P<0.0001
Uveitis	19 (17.9%)	17	0	
Both	18 (16.9%)	18	0	
Modality to stop B				
Lengthening intervals	104 (76.5%)	45	59	χ^2 3.4 p<0.049
Reduction of dose	25 (18.4)	6	19	
Abrupt	16 (11.8%)	8	8	
Duration of decalage of B	6 (0-22)	6 (0-19)	6 (0-22)	NS
Modality to stop concomitant				
Lengthening intervals	21 (15.4%)	9	12	NS
Reduction of dose	32 (23.5%)	10	22	
Abrupt	36 (26.5%)	12	24	

m: median, N: number, R: range, pOligo: persistent oligoarthritis, eOligo: extended oligoarthritis, Poli: polyarticular, JIA: juvenile idiopathic arthritis, JADAS10: Juvenile Arthritis Disease Activity Score 10, CHAQ: Childhood Health Assessment Questionnaire, ESR: erythrocyte sedimentation rate, CRP: C-reactive protein, B: biologics, Tp: therapy.